1-4 of 4
Torsten Dreier
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase 2 Study of Efgartigimod, a Novel FcRn Antagonist, in Adult Patients with Primary Immune Thrombocytopenia

Adrian C. Newland, Blanca Sánchez-González, László Rejtő, Miklos Egyed, Nataliya Romanyuk, Marie Godar, Katrien Verschueren, Domenica Gandini, Peter Ulrichts, Jon Beauchamp, Torsten Dreier, E. Sally Ward, Marc Michel, Howard A. Liebman, Hans De Haard, Nicolas Leupin, David J. Kuter
Journal: Blood
Blood (2019) 134 (Supplement_1): 895.
https://doi.org/10.1182/blood-2019-128022
Published: 2019
Journal Articles

Argx-113, a Novel Fc-Based Approach for Antibody-Induced Pathologies Such As Primary Immune Thrombocytopenia

Peter Ulrichts, PhD, Thierry Cousin, MD, Torsten Dreier, PhD, Hans de Haard, PhD, Nicolas Leupin, MD
Journal: Blood
Blood (2016) 128 (22): 4919.
https://doi.org/10.1182/blood.V128.22.4919.4919
Published: 2016
Journal Articles

ALX-0081 Nanobody ™ , an Engineered Bivalent Anti-Thrombotic Drug Candidate with Improved Efficacy and Safety as Compared to the Marketed Drugs.

Karen Silence, Heidi Jonckheere, Peter Casteels, Jan Roodt, Muriel Meiring, Seb Lamprecht, Martin IJsseldijk, Kristi de Smet, Bob van der Jeugt, Flip de Groot, Torsten Dreier
Journal: Blood
Blood (2006) 108 (11): 896.
https://doi.org/10.1182/blood.V108.11.896.896
Published: 2006
Journal Articles

Natural Killer Cell–Mediated Eradication of Neuroblastoma Metastases to Bone Marrow by Targeted Interleukin-2 Therapy

Holger N. Lode, Rong Xiang, Torsten Dreier, Nissi M. Varki, Stephen D. Gillies, Ralph A. Reisfeld
Journal: Blood
Blood (1998) 91 (5): 1706–1715.
https://doi.org/10.1182/blood.V91.5.1706
Published: 1998